58145-33-8

Usage

Uses

Used in Pharmaceutical Applications:
1-(6-amino-9H-purin-9-yl)-3-chloropropan-2-ol is used as a potential pharmaceutical agent for [application reason]. Its purine base could be exploited for targeting specific biological processes, while the chloropropanol group may offer opportunities to modulate its activity or improve its pharmacokinetic properties.
Used in Organic Synthesis:
In the chemical industry, 1-(6-amino-9H-purin-9-yl)-3-chloropropan-2-ol is used as a chemical intermediate for the preparation of other compounds. Its unique structure allows for further functionalization and incorporation into more complex molecules, potentially leading to novel pharmaceuticals or other valuable chemicals.
Further research and testing are required to fully understand the specific properties and potential applications of 1-(6-amino-9H-purin-9-yl)-3-chloropropan-2-ol, as well as to optimize its synthesis and evaluate its safety and efficacy in various contexts.

Upstream product

• 66224-66-6 adenine 
• 106-89-8 epichlorohydrin 

Relevant academic research and scientific papers

Ring-opening of 3-β-D-ribofuranosyl-3,7,8,9-tetrahydropyrimido [1,2-i]purin-8-ol and preparation of 2-thio- and 2-aza-adenosine derivatives

The adduct 3-β-D-ribofuranosyl-3,7,8,9-tetrahydropyrimido[1,2-i]purin- 8-ol (2), obtained from adenosine and epichlorohydrin, underwent ring fission at basic conditions. The initial ring-opening took place at C2 of the pyrimidine unit resulting in 2-(5-amino-1-β-D-ribofuranosyl-imidazol-4-yl)-1,4,5,6- tetrahydropyrimidin-5-ol (3). Also the tetrahydropyrimidine ring of 3 could be opened resulting in 5-amino-1-(β-D-ribofuranosyl)-imidazole-4-(N-3-amino-2- hydroxyl-propyl)-carboxamide (4). In hot acid conditions, 2 was both deglycosylated and ring-opened yielding 2-(5-amino-imidazol-4-yl)-1,4,5,6- tetrahydropyrimidin-5-ol (7) as the final product. When reacting 3 with CS2 or HNO2 ring-closure took place and 3-β-D-ribofuranosyl-3,4,7,8,9- pentahydropyrimido[1,2-i]purin-8-ol-5-thione (5), and 3-β-D-ribofuranosyl- imidazo[4,5-e]-3,7,8,9-tetrahydropyrimido[1,2-c][1,2,3]triazine-8-ol (6), respectively, were obtained. Also, the pyrimidine ring of the epichlorohydrin adduct with adenine, 10-imino-5,6-dihydro-4H,10H-pyrimido[1,2,3-cd]purin-5-ol (10), underwent ring fission and the product was identified as 3-hydroxy-1,2,3,4-tetrahydroimidazo[1,5-a]pyrimidine-8-carboximidamide (11). Copyright Taylor & Francis Group, LLC.